Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery
NCT00381641 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 63
Last updated 2025-03-28
Summary
This phase II trial studies how well sunitinib malate works in treating patients with thyroid cancer that did not respond to iodine I 131 (radioactive iodine) and cannot be removed by surgery. Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
Conditions
- Differentiated Thyroid Gland Carcinoma
- Recurrent Thyroid Gland Carcinoma
- Refractory Thyroid Gland Carcinoma
- Stage III Thyroid Gland Follicular Carcinoma AJCC v7
- Stage III Thyroid Gland Medullary Carcinoma AJCC v7
- Stage IV Thyroid Gland Follicular Carcinoma AJCC v7
- Stage IV Thyroid Gland Medullary Carcinoma AJCC v7
- Stage IV Thyroid Gland Papillary Carcinoma AJCC v7
- Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7
- Stage IVA Thyroid Gland Medullary Carcinoma AJCC v7
- Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7
- Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7
- Stage IVB Thyroid Gland Medullary Carcinoma AJCC v7
- Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7
- Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7
- Stage IVC Thyroid Gland Medullary Carcinoma AJCC v7
- Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7
- Thyroid Gland Oncocytic Carcinoma
- Unresectable Thyroid Gland Carcinoma
Interventions
- OTHER
-
Laboratory Biomarker Analysis
Optional correlative studies
- OTHER
-
Pharmacogenomic Study
Optional correlative studies
- DRUG
-
Sunitinib
Given PO
- DRUG
-
Sunitinib Malate
Given PO
Sponsors & Collaborators
-
National Cancer Institute (NCI)
lead NIH
Principal Investigators
-
Tanguy Y Seiwert · University of Chicago Comprehensive Cancer Center
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2006-08-29
- Primary Completion
- 2016-12-31
- Completion
- 2024-12-10
Countries
- United States
Study Locations
More Related Trials
-
Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer
NCT03463460 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy
NCT00890747 ·Status: COMPLETED ·Phase: PHASE1
-
Sunitinib Malate in Treating Patients With Small Cell Lung Cancer
NCT00953459 ·Status: TERMINATED ·Phase: PHASE2
-
Sunitinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT00398112 ·Status: COMPLETED ·Phase: PHASE2
-
Sunitinib Malate in Treating Patients With Uterine Cervical Cancer That is Stage IVB, Recurrent, or Cannot Be Removed By Surgery
NCT00389974 ·Status: COMPLETED ·Phase: PHASE2
-
Sunitinib in Treating Patients With Relapsed or Refractory Diffuse or Mediastinal Large B-Cell Lymphoma
NCT00392496 ·Status: COMPLETED ·Phase: PHASE2
-
Sunitinib in Treating Patients With Newly Diagnosed Stage II or Stage III Breast Cancer That Can Be Removed by Surgery
NCT00482755 ·Status: COMPLETED ·Phase: PHASE2
-
Sunitinib and Irradiated Donor Lymphocytes in Treating Patients With Metastatic Kidney Cancer
NCT00853125 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of Sunitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands
NCT00886132 ·Status: COMPLETED ·Phase: PHASE2
-
Sunitinib as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
NCT01210053 ·Status: UNKNOWN ·Phase: PHASE2
-
Thyroid Cancer and Sunitinib
NCT00510640 ·Status: COMPLETED ·Phase: PHASE2
-
Sunitinib Malate in Treating Patients With Unresectable or Metastatic Kidney Cancer or Other Advanced Solid Tumors
NCT00499135 ·Status: COMPLETED ·Phase: PHASE1
-
Sunitinib in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
NCT00451048 ·Status: COMPLETED ·Phase: PHASE2
-
Sunitinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer Who Have Tumor Cells in the Bone Marrow
NCT00824538 ·Status: TERMINATED ·Phase: PHASE2
-
Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines (Style Trial)
NCT03449173 ·Status: UNKNOWN ·Phase: PHASE2
-
Sunitinib in Treating Patients With Relapsed Multiple Myeloma
NCT00514137 ·Status: COMPLETED ·Phase: PHASE2
-
Study Of SU011248 Versus Chemotherapy For Patients With Previously Treated Triple Receptor Negative Breast Cancer
NCT00246571 ·Status: COMPLETED ·Phase: PHASE2
-
Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas
NCT00474994 ·Status: COMPLETED ·Phase: PHASE2
-
Surufatinib as Neoadjuvant Treatment for Locally Advanced or Metastatic Differentiated Thyroid Cancer
NCT05989425 ·Status: RECRUITING ·Phase: PHASE2
-
Sunitinib in Treating Patients With Metastatic Germ Cell Tumors That Have Relapsed or Not Responded to Treatment
NCT00453310 ·Status: COMPLETED ·Phase: PHASE2
-
Sutent Adjunctive Treatment of Differentiated Thyroid Cancer
NCT00668811 ·Status: COMPLETED ·Phase: PHASE2
-
Sunitinib Malate in Treating Patients With Locally Recurrent, Locally Advanced, Unresectable, or Metastatic Urinary Tract Cancer
NCT01118039 ·Status: UNKNOWN ·Phase: PHASE2
-
Sunitinib Before and After Surgery in Treating Patients With Stage IV Kidney Cancer
NCT00717587 ·Status: UNKNOWN ·Phase: PHASE2
-
Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
NCT01164228 ·Status: COMPLETED ·Phase: PHASE2
-
A Clinical Trial Comparing Efficacy And Safety Of Sunitinib And Capecitabine
NCT00373113 ·Status: TERMINATED ·Phase: PHASE3